Source:http://linkedlifedata.com/resource/pubmed/id/21830439
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
107-108
|
| pubmed:dateCreated |
2011-8-11
|
| pubmed:abstractText |
A combination regimen of up to three cytotoxic agents have been delivered in the West whereas single agent or two-drug combination regimens have been used sequentially in Japan for patients with unresectable/recurrent gastric cancer. Patients treated with chemotherapy in a single Japanese institution were analyzed to identify patients who benefit from higher lines of chemotherapy.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0172-6390
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
58
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1041-5
|
| pubmed:meshHeading | |
| pubmed:articleTitle |
Impact of clinical response to first-line chemotherapy on gastric cancer patients treated with second-line and third-line chemotherapy.
|
| pubmed:affiliation |
Department of Surgery II, Nagoya University School of Medicine, Nagoya, Aichi, Japan. ykodera@med.nagoya-u.ac.jp
|
| pubmed:publicationType |
Journal Article
|